|Other Names||Complement component C1q receptor, C1q/MBL/SPA receptor, C1qR, C1qR(p), C1qRp, CDw93, Complement component 1 q subcomponent receptor 1, Matrix-remodeling-associated protein 4, CD93, CD93, C1QR1, MXRA4|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1431c was selected from the C-term region of human CD93. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Receptor (or element of a larger receptor complex) for C1q, mannose-binding lectin (MBL2) and pulmonary surfactant protein A (SPA). May mediate the enhancement of phagocytosis in monocytes and macrophages upon interaction with soluble defense collagens. May play a role in intercellular adhesion.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
|Tissue Location||Highly expressed in endothelial cells, platelets, cells of myeloid origin, such as monocytes and neutrophils. Not expressed in cells of lymphoid origin|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CD93 is a cell-surface glycoprotein and type I membrane protein that was originally identified as a myeloid cell-specific marker. This protein was once thought to be a receptor for C1q, but now is thought to instead be involved in intercellular adhesion and in the clearance of apoptotic cells. The intracellular cytoplasmic tail of this protein has been found to interact with moesin, a protein known to play a role in linking transmembrane proteins to the cytoskeleton and in the remodelling of the cytoskeleton.
Ikewaki,N.,Microbiol. Immunol. 51 (12), 1189-1200 (2007)Mehrle,A., Nucleic Acids Res. 34 (DATABASE ISSUE), D415-D418 (2006)Zhang,M., Immunology 115 (1), 63-73 (2005)
If you have any additional inquiries please email technical services at email@example.com.